Sanjay V. Malhotra
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (10)
In vivo functional evaluation of FH FOLR1-CAR T cells in metastatic PDX model. A, Average radiance of pulmonary PDX OS9 disease measured over 180 days from tumor inoculation by tail vein in mice treated with FOLR1-CART vs. NT T cells. B, Kaplan–Meier survival curves of xenografts treated with NT or FOLR1-CAR T cells. n = 5 per group. Statistical difference in survival evaluated using Mantel–Cox log-rank test. C, Bioluminescence imaging of metastatic pulmonary PDX OS9 tumor injected by tail vein in mice treated with NT or FOLR1-CAR T cells. Radiance scale indicates progressive metastatic osteosarcoma from blue to red. *Day 20 images use a minimum radiance cutoff of 3e4 p/second/cm 2 /sr to show the presence of tumor engraftment prior to treatment. Minimum radiance cutoff of 3e6 p/second/cm 2 /sr used for posttreatment images to avoid noise created by excess radiance detected. X indicates death. D, day.
Year:
2025
FH FOLR1-CART antitumor activity against patient-derived osteosarcoma cell lines in vitro . A, FOLR1 expression detected by flow cytometry by a panel of patient-derived osteosarcoma cell lines OS186, OS9, OS525, OS766, OS742, OS33, and OS457. Red, tumor stained with PE-labeled anti-FOLR1; unfilled, isotype control. B and C, FH FOLR1-CAR T cell–induced tumor cell lysis detected by flow cytometry after co-culture at 24 hours at E:T ratios of 1:1 ( B ) and 10:1 ( C ) in FOLR1-positive patient-derived osteosarcoma cell lines OS186, OS525, OS766, and OS742. No tumor killing was seen in the FOLR1-negative cell line OS457. D, Cytokines released by FH FOLR1-CART vs. NT T cells co-cultured with patient-derived osteosarcoma cell lines. Concentration (pg/mL) of secreted IL-2, IFN-γ, and TNFα detected in co-culture supernatant following 24 hours of 1:1 T cell-to-tumor cell ratio. *, P
Year:
2025
In vivo functional evaluation of FH FOLR1-CAR T cells in a metastatic U-2 OS xenograft model. A, Average radiance of pulmonary osteosarcoma disease measured over 180 days from tumor inoculation by tail vein in mice treated with FH FOLR1-CART vs. NT T cells. B, Kaplan–Meier survival curves of xenografts treated with NT or FH FOLR1-CAR T cells. n = 3 per group. Statistical difference in survival evaluated using Mantel–Cox log-rank test. C, Biolumiscence imaging of metastatic pulmonary U-2 OS tumor injected by tail vein in mice treated with NT or FH FOLR1-CAR T cells. Radiance scale indicates progressive metastatic osteosarcoma from blue to red. *Day 13 images use a minimum radiance cutoff of 5e4 p/second/cm 2 /sr to show the presence of tumor engraftment prior to treatment. A minimum radiance cutoff of 2e5 p/second/cm 2 /sr was used for posttreatment images to avoid noise created by excess radiance detected. X indicates death. D, day. D and E, Axial noncontrast CT scan in lung windows in two different mice. D, Lobulated soft tissue density (solid arrow) with spiculated margins is present in the right upper lung of mouse treated with NT T cells at 133 days after osteosarcoma injection by tail vein. E, Note the normal appearance of the right upper lung, with normal lung markings and the absence of soft tissue mass (open arrow), of mouse treated with FH FOLR1-CAR T cells at same time point. No other lesions were present within the remainder of the lungs. F, H&E stain of lung tissue harvested from mouse treated with FH FOLR1-CART at 5× magnification. No tumors or any sign of disease observed within sections taken. G, H&E stain of lung tissue harvested from mouse treated with NT T cells at 5× magnification. Expanding and effacing the normal lung are numerous poorly circumscribed, invasive, moderately cellular proliferation of neoplastic mesenchymal cells arranged in trabeculae and streams. Neoplastic cells occasionally surround eosinophilic osteoid and islands of the basophilic cartilaginous matrix.
Year:
2025
In vivo functional evaluation of FH FOLR1-CART in a localized U-2 OS xenograft model. A, Average radiance emitted by tumor measured over 180 days from intrafemoral tumor inoculation in mice treated with FH FOLR1-CART vs. NT T cells. B, Kaplan–Meier survival curves of xenografts treated with NT or FH FOLR1-CAR T cells. n = 2 per group. Statistical differences in survival evaluated using Mantel–Cox log-rank test. C, Bioluminescence imaging of localized U-2 OS tumor inoculated intrafemorally in mice treated with NT or FH FOLR1-CAR T cells. Radiance scale indicates progressive osteosarcoma from blue to red. *Day 13 images use a minimum radiance cutoff of 1e6 p/second/cm 2 /sr to show the presence of tumor engraftment prior to treatment. Minimum radiance cutoff of 2.5e6 p/second/cm 2 /sr used for posttreatment images to avoid noise created by excess radiance detected. X indicates death. D, day. D, Axial T2-weighted fat-saturated images of mouse femur treated with NT T cells at 84 days after local osteosarcoma cell line inoculation. Note the T2 hyperintense lobulated soft tissue mass (solid white arrow) involving the distal right femur. The bladder (star), noted more medially, also demonstrates T2 hyperintensity. E, The bone underlying the mass at 84 days after tumor cell line injection demonstrates abnormal morphology with diffuse marrow signal change and cortical destruction (open arrow). F, Axial T2-weighted fat-saturated images of mouse femur treated with FH FOLR1-CAR T cells at 84 days after tumor inoculation. Note the absence of any soft tissue mass or bone marrow signal changes of the distal right femur (solid arrows).
Year:
2025
FOLR1 expression by osteosarcoma from various genomic databases. A, mRNA expression of FOLR1 in various pediatric malignancies from the St. Jude PCGP database. Increased FOLR1 mRNA expression demonstrated in osteosarcoma, as well as other solid tumors such as ependymoma and renal cell carcinoma. Line across denotes median FPKM. B, Data obtained from the PIVOT demonstrate high FOLR1 mRNA expression by osteosarcoma in addition to ependymoma. Line across denotes median TPM. C, Data obtained from the Open Pediatric Cancer Project v15 shows increased FOLR1 mRNA expression by osteosarcoma, ependymoma, renal cell carcinoma, and choroid plexus carcinoma. Line across denotes median TPM. ALL, acute lymphoblastic leukemia.
Year:
2025
Metastatic and relapsed osteosarcoma remains difficult to treat despite advanced surgical techniques, intensified chemotherapy, and targeted therapies. Adoptive immunotherapies such as chimeric antigen receptor (CAR) T cells are in their nascent stage but remain a viable therapeutic strategy for patients with aggressive solid tumors such as osteosarcoma. Folate receptor-α (FOLR1) has been functionally implicated in osteosarcoma pathophysiology, providing rationale as a potential therapeutic target. We recently advanced a FOLR1-specific CAR T-cell product (FH FOLR1-CART) into a trial in infant acute myeloid leukemia (NCT06609928) and now evaluate this CAR construct against osteosarcoma. We provide comprehensive FOLR1 transcript and protein expression profile in patients with osteosarcoma, cell lines, and patient-derived xenografts, substantiating its significance as a therapeutic target. We further evaluate the in vitro and in vivo efficacy of FH FOLR1-CART in both standard and patient-derived osteosarcoma cell lines and xenograft models. FOLR1 transcript is expressed in the overwhelming majority of osteosarcoma primary patient specimens, osteosarcoma cell lines, and patient-derived models. FH FOLR1-CART exhibits robust in vitro activation and potent cytotoxicity against FOLR1-expressing osteosarcoma cell lines and primary osteosarcoma patient samples. More importantly, FH FOLR1-CART demonstrates potent antitumor activity in both localized and metastatic in vivo cell-derived and patient-derived xenograft models, with complete tumor eradication. These results demonstrate a potential therapeutic option for patients with advanced osteosarcoma. FH FOLR1-CART is advancing to an early-phase trial in relapsed/refractory osteosarcoma at Fred Hutchinson Cancer Center and Seattle Children’s Hospital. Significance: FOLR1 expression has previously been implicated in the pathogenesis of treatment-resistant osteosarcoma. This report demonstrates FOLR1 expression by most osteosarcoma tumors and provides preclinical evidence of robust antitumor activity both in vitro and in vivo against xenograft osteosarcoma models exhibited by FH FOLR1-CART. These data support ongoing efforts for clinical translation of FH FOLR1-CART to an early-phase clinical trial for patients with aggressive osteosarcoma.
Year:
2025
FH FOLR1-CART antitumor activity against U-2 OS osteosarcoma cell line in vitro . A, FOLR1 expression detected by flow cytometry by U-2 OS, WSU-AML (standard M7, FOLR1-positive AML), and Kasumi (standard FOLR-negative AML). Red, tumor stained with PE-labeled anti-FOLR1; unfilled, isotype control. B, Increased FH FOLR1-CAR T cell–induced tumor cell lysis detected by flow cytometry after co-culture at 6 and 24 hours at various E:T ratios, compared with tumor cell lysis induced by NT T cells. C, Representative images from the IncuCyte imaging platform at hours 0 and 20.5 of co-culture. Green, live U-2 OS tumor cells; red, dead cells. D, Concentration (pg/mL) of secreted IL-2, IFN-γ, and TNFα detected in co-culture supernatant following 24 hours of 1:1 CD8 + T cell-to-U-2 OS ratio. *, P
Year:
2025
Metastatic and relapsed osteosarcoma remains difficult to treat despite advanced surgical techniques, intensified chemotherapy, and targeted therapies. Adoptive immunotherapies such as chimeric antigen receptor (CAR) T cells are in their nascent stage but remain a viable therapeutic strategy for patients with aggressive solid tumors such as osteosarcoma. Folate receptor-α (FOLR1) has been functionally implicated in osteosarcoma pathophysiology, providing rationale as a potential therapeutic target. We recently advanced a FOLR1-specific CAR T-cell product (FH FOLR1-CART) into a trial in infant acute myeloid leukemia (NCT06609928) and now evaluate this CAR construct against osteosarcoma. We provide comprehensive FOLR1 transcript and protein expression profile in patients with osteosarcoma, cell lines, and patient-derived xenografts, substantiating its significance as a therapeutic target. We further evaluate the in vitro and in vivo efficacy of FH FOLR1-CART in both standard and patient-derived osteosarcoma cell lines and xenograft models. FOLR1 transcript is expressed in the overwhelming majority of osteosarcoma primary patient specimens, osteosarcoma cell lines, and patient-derived models. FH FOLR1-CART exhibits robust in vitro activation and potent cytotoxicity against FOLR1-expressing osteosarcoma cell lines and primary osteosarcoma patient samples. More importantly, FH FOLR1-CART demonstrates potent antitumor activity in both localized and metastatic in vivo cell-derived and patient-derived xenograft models, with complete tumor eradication. These results demonstrate a potential therapeutic option for patients with advanced osteosarcoma. FH FOLR1-CART is advancing to an early-phase trial in relapsed/refractory osteosarcoma at Fred Hutchinson Cancer Center and Seattle Children’s Hospital. Significance: FOLR1 expression has previously been implicated in the pathogenesis of treatment-resistant osteosarcoma. This report demonstrates FOLR1 expression by most osteosarcoma tumors and provides preclinical evidence of robust antitumor activity both in vitro and in vivo against xenograft osteosarcoma models exhibited by FH FOLR1-CART. These data support ongoing efforts for clinical translation of FH FOLR1-CART to an early-phase clinical trial for patients with aggressive osteosarcoma.
Year:
2025
The N‐bridgehead heterocyclic structure is an abundant motif in a multitude of natural products. This structural feature is of high interest because it is present in many different bioactive molecules, many of which are well‐established pharmaceuticals. The introduction of a sulfone group into the N‐bridgehead system yields a new core structure containing a N‐bridgehead sulfonamide. While linear sulfonamides can be found in natural products, only artificial cyclic sulfonamides are known to date. Applications of related cyclic sulfonamide compounds include matrix metalloproteinase inhibitors, potential HIV and cancer therapeutics, and anti‐inflammatory compounds. To explore the potential bioactivity of the N‐bridgehead sulfonamide scaffold, a synthetic route toward these scaffolds is developed and their bioactivity is explored against different cancer cell lines.
Year:
2025
Year:
2022
Collaborators (5)
Richard Gorlick
The University of Texas MD Anderson Cancer Center
Lara Davis
Fred Hutch Cancer Center
Soheil Meshinchi
Fred Hutchinson Cancer Research Center
Raisa Glabman
Fred Hutch Cancer Center
Elizabeth Loggers
Fred Hutchinson Cancer Research Center
Make your next move.
Prepare your application
Review drafts before you send them.